Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity ...

AZ said in the summer that anifrolumab had met its objectives in the phase 3 TULIP-2 trial, around a year after it flunked an earlier study (TULIP-1) which had caused many to dismiss any prospect ...

Anifrolumab was all-but written off in 2018 after failing the phase 3 TULIP-1 trial, but bounced back with positive data from a second study – TULIP-2 – that has proved sufficient for the FDA ...

This retrospective study analyzed data from 354 participants (anifrolumab group) in the TULIP-1 and -2 trials and 561 participants as real-world external controls. Participants in the anifrolumab ...

TULIP II was a phase III trial, meaning the drug has passed the early trial phases successfully and these results now pave the way for applications to be made for anifrolumab to be licensed for use in ...

The likelihood of experiencing an increase in Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index within 208 weeks was lower for patients in the ...

The anifrolumab arm included patients who initiated 300 mg anifrolumab in the Treatment of Uncontrolled Lupus via the Interferon Pathway trials; real-world (RW) external controls from the ...